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DLC-1 encodes a Rho GTPase-activating protein (RhoGAP)
and negative regulator of specific Rho family proteins (RhoA–C
andCdc42).DLC-1 is amulti-domain protein,with theRhoGAP
catalytic domain flanked by an amino-terminal sterile  motif
(SAM) and a carboxyl-terminal START domain. The roles of
these domains in the regulation of DLC-1 function remain to be
determined.Weundertook a structure-function analysis involv-
ing truncation andmissensemutants of DLC-1.We determined
that the amino-terminal SAM domain functions as an autoin-
hibitory domain of intrinsic RhoGAP activity. Additionally, we
determined that the SAM and START domains are dispensa-
ble for DLC-1 association with focal adhesions.We then char-
acterized several mutants for their ability to regulate cell
migration and identified constitutively activated and domi-
nant negative mutants of DLC-1. We report that DLC-1 acti-
vation profoundly alters cell morphology, enhances protru-
sive activity, and can increase the velocity but reduce
directionality of cell migration. Conversely, the expression of
the amino-terminal domain of DLC-1 acts as a dominant neg-
ative and profoundly inhibits cell migration by displacing
endogenous DLC-1 from focal adhesions.
Members of the Rho family of small GTPases are intimately
involved in many aspects of cell function including cell cycle
progression, intracellular trafficking, and control of cell divi-
sion (1). The well studied RhoGTPases RhoA, Cdc42, and Rac1
are best known for their key roles in regulation of the actin
cytoskeleton and cell migration. Thus RhoA is essential to actin
stress fiber and focal contact formation, Rac1 is vital to forma-
tion of actin networks at the leading edge ofmigrating cells, and
Cdc42 triggers actin filament extension and bundling in filop-
odia (2).
The activation state of RhoGTPases is regulated primarily by
the conjoint effects of Rho-specific guanine nucleotide
exchange factors (GEFs)4 and GTPase-activating domains
(GAPs). RhoGEFs promote GDP/GTP exchange to favor for-
mation of the active GTP-bound protein, whereas RhoGAPs
stimulate the intrinsic weak GTP hydrolysis activity of Rho
GTPases and promote formation of the inactive GDP-bound
GTPase (1). Although there are 20 members of the Rho family,
there is far greater complexity with regards to the regulatory
proteins that control GDP/GTP cycling. There are 90 human
RhoGEFs and 80 RhoGAPs based on genome analysis (1, 3, 4).
This diversity reflects the ability of each Rho GTPase to be
regulated by a diverse spectrum of extracellular stimuli and in
precise temporal and spatial patterns to dictate their divergent
roles in cell physiology. In particular, the role and regulation of
specific RhoGEFs in controlling Rho GTPase activity has been
the subject of intense research evaluation. In contrast, far less
attention has been focused on the role and mechanisms by
which RhoGAPs may regulate the spatiotemporal activation
and function of Rho GTPases.
The human RhoGAP DLC-1 and its rat homolog
p122RhoGAP have elicited substantial interest of late. DLC-1
exhibits characteristics of a tumor suppressor gene with a dem-
onstrated role in growth inhibition inmany types of carcinomas
(5–8). The highly related proteinsDLC-2 andDLC-3 have been
linked to similar inhibitory effects on cell growth and function
(9, 10). Absence of the DLC-1 protein in tumors may be due
either to deletion of the gene or to suppression of its expression
caused bymethylation of the promoter (11). Because activation
of Rho GTPases has been associated with human oncogenesis
(12), the tumor suppressor function has been attributed to its
ability to negatively regulate Rho GTPase activity, although
RhoGAP-independent mechanisms of DLC-1 growth regula-
tion may also exist.
DLC-1/p122RhoGAP and related isoforms are comprised of
three readily recognizable functional domains (13). There is a
sterile  motif (SAM) domain at the amino terminus, a central
RhoGAP catalytic domain found in all RhoGAPs, and a carbox-
yl-terminal steroidogenic acute regulatory related lipid transfer
(START) domain. The 70-amino acid SAM domains are
found in over 200 human proteins and are known to serve as
protein-protein interaction domains (14). However, the recent
structural determinations of the DLC-2 SAM domain suggest
that this SAM domain is structurally distinct and hencemay be
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functionally distinct from canonical SAM domains (15, 16).
The RhoGAP domain of DLC-1 has been shown to stimulate
RhoA inactivation in vitro and in vivo (5, 17). GAP activity in
vitro has also been described for Cdc42 but not Rac. Consistent
with RhoA GAP activity, overexpression of p122RhoGAP in
fibroblasts led to a loss of focal contacts and stress fibers (18);
this was also true of DLC-1 when overexpressed in carcinoma
cells (6). The210-amino acid STARTdomains are found in 15
distinct proteins, either alone (e.g. STARD4) or as with DLC-1,
associated with other protein domains (19). Some have been
shown to bind lipids or sterols, and START domain-containing
proteins exhibit very distinct subcellular locations. A recent
study evaluated the role of the SAM and START domains in
DLC-1 function and found that the START domain was critical
for DLC-1 inhibition of actin stress fiber formation and growth
(6). However, as described in the present study, these analyses
may have utilized an inactive RhoGAP domain. Therefore, the
precise functions of the SAM and START domains in the reg-
ulation ofDLC-1 subcellular localization andRhoGAP catalytic
activity remain to be determined.
Studies of the subcellular localization of DLC-1 present a
complex picture. Several reports suggest that DLC-1 is local-
ized at focal adhesions (20–22), whereas another study
described localization to caveolae (23), and a third study found
a diffuse distribution in the cytosol (7). The related DLC-2 and
DLC-3 proteins have also been reported to localize to focal
adhesions (10, 24). These reports may not be incompatible; a
recent study has DLC-1 linked to focal adhesions via binding of
the DLC-1 amino terminus to the focal contact protein tensin,
as well a binding of the tensin-DLC-1 complex to caveolin (21).
In three recent studies the interactions between DLC family
members and the tensin family of focal adhesion proteins
(tensins 1–3, c-ten) were determined. Thus the interaction
between DLC-1 and c-ten has been mapped to a nonphospho-
rylation dependent binding of the Src homology 2 domain of
c-ten to a short peptidemotif (440SIYDNV) in the amino termi-
nus of DLC-1; mutation of the critical Tyr442 residue abolishes
the interaction (22). Another study (25) showed that DLC-1
and DLC-3 bound tensin1 via their Src homology 2 and phos-
photyrosine-binding domains, with the former predominating.
Although substantial work has been done on the role of
DLC-1 in cell growth regulation, there is less information avail-
able concerning its effects on cytoskeletal function. To further
understand DLC-1 structure-function relationships in that
context, we developed a series of deletion and point mutants of
DLC-1 and characterized them in terms of GAP activity, sub-
cellular localization, and effects on cell morphology and motil-
ity. Our findings identified both gain-of-function constitutively
activated and dominant inhibitory mutants of DLC-1. Utilizing
these mutants, we determined that activation of DLC-1 can
contribute to increased velocity of migration but decreased
directionality. The amino-terminal domain of DLC-1 can block
the effects of DLC-1 on migration, likely by displacing active
DLC-1 from focal adhesions.
EXPERIMENTAL PROCEDURES
Cell Culture—HEK293 cells were maintained in Dulbecco’s
modification of Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (Sigma).MDA-MB-231 andMDA-MB-
468 breast cancer cells were obtained from the ATCC (Rock-
ville, MD) and grown in DMEM/Ham’s F-12 medium supple-
mented with 10% fetal bovine serum.
Plasmids—For mammalian cell expression of green fluores-
cent protein tagged DLC-1 proteins, the full-length (1–1091
amino acids) and truncated sequences of the DLC-1 cDNA
(GenBankTM accession number NM_006094) were generated
by PCR and subcloned into the BamHI site of pEGFP-N1 (BD
Biosciences). The truncated fragments of DLC-1 are as follows:
DLC-1 SAM (77–1091 amino acids), DLC-1 N (609–1091
amino acids), DLC-1 START (875–1091 amino acids), DLC-1
START (1–878 amino acids), DLC-1 N1 (1–638 amino
acids), DLC-1 SAM (1–83 amino acids), and DLC-1 RhoGAP
(609–878 amino acids). Serial amino-terminal truncations of
DLC-1 ending with residues 252, 439, 609, and 629 were gen-
erated by PCR from full-length pEGFP-DLC-1, and serial car-
boxyl-terminal truncations of DLC-1 ending with residues 850,
828, and 878 were generated by PCR from pEGFP-DLC-1 N
(609–1091) and subcloned into the BamHI site of pEGFP-N1.
Additional mutant constructs are explained in the figure leg-
ends and text. For expression of glutathione S-transferase
(GST) fusion recombinant protein, cDNA sequences for full-
length DLC-1, DLC-1 SAM, and DLC-1 RhoGAP domain
were subcloned into the pGEX-5X-3 (GE Healthcare) bacterial
expression vector. All of the plasmid cDNA coding sequences
were sequence-verified before use. pGEX plasmids for expres-
sion of GST fusions of wild type human RhoA have been
described previously (26). The pAX142-RhoA (63L) and
pAX142-Cdc42(12V) mammalian expression vectors for acti-
vated Rho GTPases have been described previously (27).
Confocal Microscopy—MDA-MB-468 cells on coverslips
were transiently transfected with various EGFP-tagged DLC-1
constructs using LipofectamineTM 2000 (Invitrogen). After
24 h of transfection, the cells were fixed with 4% paraformalde-
hyde for 5 min, permeabilized with 0.2% (v/v) Triton X-100 for
5 min at room temperature, and stained with either Alexa Fluo
568-phalloidin (Molecular Probes) for F-actin or anti-vinculin
antibody (Sigma) or monoclonal anti-DLC-1 antibody (BD
Biosciences) followed by incubation with fluorescently conju-
gated secondary antibody. The anti-DLC-1 antibody was
shown to be specific versus other members of the DLC family
(data not shown). For cotransfection experiments, HEK293
cells plated in 24-well plates were transiently transfected with
0.15 g of pEGFP-DLC-1 SAM and 0.45 g of pAX142-
RhoA(63L) or pAX142-Cdc42(12V) using LipofectamineTM
2000. Twenty-four hours after transfection, the cells were
trypsinized and replated on fibronectin-coated coverslips (10
g/ml) in DMEM supplemented with 10% fetal bovine serum
for 1 h. The cells were fixed, stained as described above, and
observed on an Olympus confocal FV300 fluorescent micro-
scope with a 60 oil immersion objective; the images were
acquired by using Olympus Fluoview software.
In Vitro RhoGAP Assay—The in vitroGAP activity of DLC-1
was measured with a fluorescence-based technique as we
described previously (5). Briefly, plasmids encodingGST fusion
proteins of DLC-1 and RhoGTPases were transformed into the
BL-21 Escherichia coli strain, and expression of the GST fusion
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proteins of DLC-1 and RhoAwas inducedwith 100mM and 250
mM isopropyl -D-1-thiogalactopyranoside for 16 h at room
temperature, respectively. Bacterially expressed Rho GTPases
were purified by glutathione-Sepharose 4B chromatography
andwere preloadedwithGTP in an exchange buffer for 1min at
37 °C. Hydrolysis assays were initiated with adding 0.30 mM
DLC-1 in an assay buffer containing 15mMMDCC-phosphate-
binding protein and 2 mM GTP-bound GTPase. The increases
in Pi production from GTP hydrolysis were measured with a
SpectraMAX Gemini (Molecular Devices) spectrofluorimeter
by checking increases in fluorescence (ex  425 nm and em 
465 nm).
RhoA Activation Assay—A GST fusion of the Rho-GTP-
binding domain of Rhotekin (amino acids 7–89), an effector of
RhoA, was used in pulldown assays to detect expression of acti-
vatedRhoA-GTPas described previously (28). In brief,HEK293
cells plated in 100 mm of culture were transfected with DLC-1
plasmids for 20 h, treated with lysophosphatidic acid for 30
min, and lysed in 300 l of ice-cold lysis buffer (50 mM Tris-
HCl, pH 7.4, 500 mM sodium chloride, 0.1% SDS, 0.5% deoxy-
cholate, 1% Triton X-100, 0.5 mM magnesium chloride, 1 mM
sodium orthovanadate, 10 g/ml leupeptin, 10 g/ml aproti-
nin, and 1mMphenylmethanesulfonyl fluoride) and clarified by
centrifugation at 14,000 rpm for 20 min at 4 °C. A 5% aliquot
was removed for determination of total quantities of the
GTPase being analyzed. Clarified lysates were then incubated
with 5 g of GST-Rhotekin Rho-GTP-binding domain fusion
protein for 1 h at 4 °C that had been precoupled to glutathione-
Sepharose 4B beads (AmershamBiosciences) andwashed three
times with the lysis buffer. The samples were analyzed by SDS-
PAGE and Western blotting using anti-RhoA antibody (BD
Biosciences) to detect bound activated GTPases. Whole cell
lysates were also analyzed for the presence of expressed RhoA
and tubulin for normalization.
Migration Analysis—Cells plated overnight were transiently
transfected with various pEGFP-DLC-1 plasmids using Lipo-
fectamineTM 2000. After 12–18 h of transfection, the cells were
trypsinized, replated sparsely on fibronetin-coated (10 g/ml)
glass-bottomed dishes in DMEM supplemented with 10% fetal
bovine serumand placed in a temperature- andCO2-controlled
chamber of a microscope equipped with 40 objective lenses.
Time lapse recording was started 30 min or 1 h after plating,
and differential interference contrast images were collected at
5-min intervals over 6 h using a CoolSnap HQ cooled charge-
coupled device (Roper Scientific) linked to a Zeiss Axiovert
200M microscope controlled by SLIDEBOOK software (Intel-
ligent Imaging, Denver, CO), or alternatively brightfield images
were collected with a high content screening instrument, BD
Pathway 855 Bioimager (BD Biosciences). To explore the
effects of Rho kinase (ROCK) inhibition on cell migration,
HEK293 cells on fibronectin-coated (10g/ml) glass-bottomed
dishes in DMEM supplemented with 10% fetal bovine serum
were treated for 3 h with 50 M of the ROCK inhibitor Y27632
(Calbiochem Inc.) before starting time lapse recording. The
velocity and persistence of migratory directionality (D/T) were
measured by manually tracking of the location of cell centroids
at each frame using Image J orMetamorph software (Molecular
Devices). Each figure shown is representative of a minimum of
two to three independent experiments analyzing 10–25 cells
each. The velocity was calculated as [total length of migration
paths (M)/time (min)] and the persistence of migration was
calculated as [net displacement (M)/total length of migration
paths (M)].
RESULTS
Distinct Roles of Amino- and Carboxyl-terminal Sequences in
Regulation of DLC-1 Subcellular Localization—Recent studies
suggest that amino-terminal sequences between the SAM and
RhoGAP domains regulate DLC-1 subcellular localization (22,
25). To further evaluate the contribution of amino- and carbox-
yl-terminal sequences in regulation of DLC-1, we generated
expression vectors that encoded more precise deletion and
truncationmutants that were coupled at the carboxyl terminus
to enhanced green fluorescent protein (EGFP) to allow us to
monitor DLC-1 expression and localization in live cells (Fig. 1).
First, we wanted to verify that our ectopic expression of a
tagged DLC-1 protein showed physiologic subcellular localiza-
tion. We utilized Western blot analyses of a series of breast
carcinoma cell lines for expression of DLC-1 and determined
that MDA-MB-468 and MDA-MB-231 cells are negative and
positive for endogenous DLC-1 protein expression, respec-
tively (data not shown).
In agreement with previous studies using amino-terminally
tagged DLC-1 fusion proteins (20–22), we found that full-
length DLC-1 with a carboxyl-terminally fused GFP partially
localized at the tips of actin filaments in MDA-MB-468 cells
(Fig. 2A) as well as showing some diffuse cytosolic distribution.
Because proteins that are ectopically expressed can be mislo-
calized, we also examined the distribution of endogenous
DLC-1 in MDA-MB-231 cells, and we found that a significant
portion of endogenous DLC-1 also seems to be localized at
actin tips within focal adhesion-like structures (Fig. 2B). These
results confirm that the ectopically expressed GFP-tagged
DLC-1 has a similar subcellular localization as endogenous
DLC-1 andmay thus be an appropriate surrogate for the endog-
enous protein.
To assess the role of amino- and carboxyl-terminal
sequences in regulation of DLC-1 function, we next evaluated
FIGURE 1. Truncation and missense mutants of DLC-1 for DLC-1 structure-
function analyses. A schematic representation of the DLC-1 truncation con-
structs is shown. The full-length and various fragments of DLC-1 cDNA were
subcloned into the EGFP-tagged expression vector, pEGFP-N1, resulting in
the expression of carboxyl-terminal GFP-tagged fusion proteins.
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the subcellular location of several GFP-tagged DLC-1 trunca-
tionmutantswhen transiently expressed inMDA-MB-468 cells
(Fig. 2C). EGFP alone exhibited a diffuse cytoplasmic and
nuclear distribution. Full-length DLC-1 largely colocalized
with vinculin-containing focal contacts. The isolated SAM
domain (DLC-1 SAM) and the isolated STARTdomain (DLC-1
START) did not show localization to focal adhesions but
showed the same localization as EGFP alone. Hence, the SAM
or START domains alone are not sufficient for focal adhesion
targeting. However, inclusion of amino-terminal sequences
upstream of the RhoGAP domain (DLC-1 N1) showed an
apparent focal adhesion localization similar to that of full-
length DLC-1. These observations suggested that the amino-
terminal region between the SAM and GAP domains was nec-
essary for the focal adhesion localization of DLC-1. These
results are consistent with recent studies determining that
DLC-1 association with focal adhesions is mediated through
tensin family protein binding to a
nonphosphorylated Tyr442 residue
that serves as a binding site for the
tensin Src homology 2 domains
(20–22). Unexpectedly, we found
that expression of any truncation
mutant lacking the amino-terminal
SAM domain caused drastic cell
rounding and formation of protru-
sions that complicated our ability to
accurately visualize the subcellular
localization abilities of these trunca-
tion mutants. However, as we dem-
onstrate in a section below, this
problem can be overcome. Supple-
mental Table S1 provides a semi-
quantitative analysis of themorpho-
logical effects and subcellular
localization of the various DLC-1
constructs.
The SAM Domain Functions as
an Autoinhibitory Regulator of
RhoGAP Activity in Vitro and in
Vivo—We further evaluated the
consequences of deletion of the
SAM domain for DLC-1 function.
As seen in Fig. 2C truncation
mutants of DLC-1 lacking the SAM
domain alone (DLC-1 SAM) or
with the entire amino-terminal
region deleted (DLC-1 N) pro-
duced dramatic changes in mor-
phology including the development
of long “neurite-like” protrusions
that often terminated in lamellipo-
dia, as well as the loss of mature vin-
culin staining focal adhesions. A
similar result was produced by
expression of DLC-1 RhoGAP
comprised of only the functional
RhoGAP domain (amino acids
609–878) linked to GFP. However, these morphological
changes and the loss of vinculin staining did not occur upon
expression of GFP alone or GFP-tagged full-length and other
mutants of DLC-1. These observations suggest that amino-ter-
minal truncations may activate DLC-1, thus leading to the
changes in cell shape. Similar morphological alterations were
also produced in other cell types including MDA-MB-231,
MDA-MB-361, and MCF-7 cells (data not shown).
The morphological changes caused by SAM domain-deleted
DLC-1 are similar to those that we have seen with inhibition of
endogenous RhoA function by overexpression of the p190
RhoGAP and the Rnd3 antagonist of RhoA (29). Therefore, we
speculated that deletion of the SAM domain rendered DLC-1
RhoGAP constitutively activated, causing inactivation of
endogenous RhoA function. Consistentwith this possibility, we
found that any of the three disabling mutations in the DLC-1
RhoGAP domain (R677E, K714E, or K718E) resulted in DLC-1
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FIGURE 2. Morphology of cells transfected with DLC-1 constructs and DLC-1 subcellular localization.
A, DLC-1 negative MDA-MB-468 cells grown on glass coverslips were transiently transfected with EGFP-tagged
full-length DLC-1, stained with rhodamine-phalloidin, and imaged with a confocal fluorescence microscope to
observe subcellular localization and the effects on cell morphology. Scale bar, 10 m. B, DLC-1 positive MDA-
MB-231 cells were fixed and stained with anti-DLC-1 antibody followed by anti-mouse secondary antibodies
conjugated to Alexa Fluor 488 and rhodamine-phalloidin (upper panel). A higher magnification of the analysis
is shown in the lower panels. Scale bar, 20 m. C, the various EGFP-tagged DLC-1 constructs indicated were
transiently transfected into MDA-MB-468 cells, and the cells were stained with an anti-vinculin antibody fol-
lowed by a Alexa Fluor 594 labeled secondary antibody. Selected overlap regions of vinculin and DLC-1 are
indicated with white arrows. Scale bar, 10 m.
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SAM mutants that were unable to induce morphological
changes in cells (see supplemental Fig. S1).
The increased biological effects of DLC-1 SAM, suggested
that the SAM may serve as an autoinhibitor domain and regu-
late intrinsic DLC-1 activity. To determine whether this was
based on an increase in intrinsic GAP catalytic activity we
undertook biochemical studies of full-length or truncated
DLC-1 proteins expressed in bacteria and analyzed via an in
vitro assay for GAP activity. We recently reported that the iso-
lated RhoGAP domain displays substantially greater GTP
hydrolysis than full-length DLC-1 in vitro (5), indicating that
the amino-terminal and/or carboxyl-terminal regions ofDLC-1
negatively regulate GAP activity. We found that full-length
DLC-1 accelerated the intrinsic GTP hydrolysis activity of
RhoA 3.3-fold and that DLC-1 SAM stimulated GTP hydrol-
ysis to a 3-fold greater degree than full-length DLC-1, whereas
the isolated RhoGAP domain stimulated to an even greater
degree (36-fold greater than the full length) (Fig. 3, A and B).
Thus we suggest that the SAM domain functions as a negative
intramolecular regulator of intrinsic DLC-1 RhoGAP catalytic
activity. This may account for the greater in vivo effects of
DLC-1 SAM versus full-length DLC-1 in causing morpholog-
ical changes. However, the greater activity of DLC RhoGAP
suggests that additional amino- and/or carboxyl-terminal
sequences may also function as autoinhibitory sequences.
Because in vitro assaysmay not precisely reflect spatially reg-
ulated events in living cells, we also evaluated the GAP activity
of DLC-1 mutants using a pulldown assay with a GST fusion
protein containing the Rhotekin Rho GTPase-binding domain,
which associates preferentially with RhoA-GTP. As seen in Fig.
3C, transient expression of full-length DLC-1 in HEK293 cells
partially reduced the level of RhoA-GTP, whereas DLC-1
SAM caused a further reduction. As we observed in vitro (Fig.
3A), the isolated RhoGAP domain exhibited greater activity in
vivo, but expression of the RhoGAP-dead version of DLC-1
RhoGAP (R718E) was without effect. Thus the cellular assay
results closely parallel the in vitro biochemical studies and illus-
trate the activating effect of the SAMdomain truncation. These
results also support the possibility that DLC-1SAM functions
as a constitutively activated version of DLC-1 and may be a
useful reagent for evaluating the role andmechanism of DLC-1
tumor suppression.
The striking change in morphology produced by activated
DLC-1 gave us the chance to more precisely define the bound-
aries of the RhoGAP domain. A previous report had indicated
that the START domain was indispensable for RhoGAP cata-
lytic activity in vivo (6). However, our deletion analyses more
precisely defining theminimal sequences required for a functional
RhoGAP domain (609–878; see supplemental Fig. S2 for a
detailed analysis) suggest that theprevious studymayhaveutilized
a nonfunctional RhoGAPdomain for their analyses.Note that our
definitionof theRhoGAPdomain (609–878)differs fromthecon-
ventional definition depicted in green in Fig. 1 (655–801) that is
based on homologies to other RhoGAPs.
Reversal of Effects of Activated DLC-1 by Rho and CDC42—
DLC-1 has been reported to have robust GAP activity for RhoA
and the closely related RhoB and RhoC proteins and to a lesser
degree for Cdc42, based on in vitro biochemical studies. Thus
we tested whether transient cotransfection of GAP-insensitive,
constitutively activated versions of RhoA and Cdc42 could
reverse the dramatic morphological changes produced by
expression of DLC-1 SAM or DLC-1 N in HEK293 cells. As
seen in Fig. 4A, cotransfection with GAP-insensitive
RhoA(Q63L) fully reversed the morphological effects and the
loss of focal adhesions caused by DLC-1 SAM, whereas
cotransfection of GAP-insensitive, active Cdc42(G12V) largely
restored the overall shape but failed to restore the presence of
mature focal contacts or actin stress fibers. The fraction of cells
with approximately normal morphology versus those with
extensive neurite-like protrusionswas quantitated and summa-
rized in Fig. 4B.
The ability of coexpressed RhoA(Q63L) to block the mor-
phologic effects of SAM-deleted truncations mutants provided
us with an approach to better evaluate the role of amino-termi-
nal sequences in regulation of DLC-1 subcellular localization.
Therefore, we evaluated the focal adhesion localization of addi-
tional amino-terminal deletion mutants of DLC-1 when coex-
pressed with RhoA(Q63L) (Fig. 4C). Deletion of the SAM
domain alone did not disrupt DLC-1 association with focal
adhesions. Although deletion of residues 1–252 (DLC-1 N1)
did not perturb DLC-1 association with focal adhesions, as
expected, deletion of residues 1–609 (DLC-1 N3) that
includes the tensin Src homology 2 domain binding motif
(SIYDNV; amino acids 440–445) was sufficient to impair
DLC-1 association with focal adhesions. Deletion of 1–439
(DLC-1 N2) also dramatically abolished focal adhesion local-
ization; this may be due to disruption of the adjacent tensin-
binding site.
Active DLC-1 Increases Cell Migration Velocity but Reduces
Directionality—Spatially directedRhoAactivation at the rear of
migrating cells is thought to facilitate directional cell migration
FIGURE 3. SAM domain deleted DLC-1 shows enhanced catalytic activ-
ity for RhoA. A, bacterially expressed full-length, SAM domain deleted
(amino acids 77–1091), and RhoGAP domain fragment (amino acids 609 –
878) of DLC-1 were purified for analysis of in vitro GAP activity. Purified
GST-RhoA fusion proteins were preloaded with GTP, and GTP hydrolysis
was monitored by incubation with a phosphate-binding protein that
undergoes a major increase in fluorescence upon binding inorganic phos-
phate. B, GTP hydrolysis activities of DLC-1 constructs. C, GTP loading of
RhoA in cells was monitored by a Rhotekin pull-down assay as described
under “Experimental Procedures.”
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(1). We thus examined DLC-1 effects in wound type migration
assays and observed that, as reported by others (6), expression
of DLC-1 results in a reduction in directional migration in this
assay (data not shown). To determine the role of specific
domains in regulating the role of DLC-1 in cell migration, we
utilized a dynamic live cell imaging approach.
For these analyses, we additionally utilized HEK 293 cells,
because they have been used extensively to study the involve-
ment of RhoA in cell migration. HEK 293 or breast tumor cells
were transiently transfected with various DLC-1 constructs,
and the effects on the velocity and directionality of cell migra-
tion were observed. Digital images were taken every 5 min for a
total of 6 h/experiment. Blot analyses verified comparable
expression of wild type and truncated DLC-1 proteins, except
that DLC-1 N (1–638) was expressed at slightly lower levels
than the other constructs (see supplemental Fig. S3). Our anal-
yses revealed profound differences in migration behavior
between controls and cells expressing wild type and mutant
DLC-1 proteins. Quantitation of results drawn from observa-
tions of multiple cells in terms of cell velocity and directionality
(Fig. 5, A and B) led to the following observations. Whereas
ectopic expression of wild type DLC-1 did not increase cell
velocity, when compared with GFP-expressing controls, cells
expressing constitutively activated DLC-1 SAM showed a
marked increase in velocity (Fig. 5A) but reduced directionality
(persistence of motion) (Fig. 5B). In contrast, cells expressing
constitutively activated DLC-1 (DLC-1 RhoGAP) displayed
similar velocity and directionality as controls. These obser-
vations suggest that both activation of the RhoGAP domain
and as yet unknown functions of the amino-terminal domain
of DLC-1 are involved in effects on motility. Interestingly,
the ROCK inhibitor Y27632 produced an increase in the
velocity of migration similar to that produced by transfec-
tion of DLC-1 SAM (Fig. 5A); however, it did not affect
directionality (Fig. 5B). This suggests that effects of active
DLC-1SAM on velocity are mediated primarily through
Rho/ROCK, whereas effects on directionality may be medi-
ated through Cdc42, which would not be affected by Y27632
or by other Rho effectors not sensitive to this inhibitor. The
dramatic effect of DLC-1 SAM on directionality is visually
illustrated in Fig. 6. Whereas a control cell expressing GFP
changed direction only five times during a 300-min time
FIGURE 4. Effects of active RhoA and Cdc42 on the morphology of cells
expressing DLC-1. A, HEK293 cells were cotransfected with pEGFP-DLC-1
SAM and vector alone (pAX142) or constructs expressing active forms of
RhoA(Q63L) or Cdc42(12V) and replated on fibronectin-coated coverslips (10
g/ml) for 1 h. The overall cell shapes as well as the localization of DLC-1 and
of actin filaments were imaged by confocal fluorescence microscopy. Scale
bar, 10 m. Unusual, multi-branched shapes were frequently seen in cells
transfected with pEGFP-DLC-1 SAM as illustrated in the top row. B, the bar
graph shows the fraction of cells displaying long, branched, neurite-like pro-
jections (black bars) and cells displaying flat morphology similar to untrans-
fected HEK293 cells (gray bars) in the experiment described in A. The means 
S.D. of 100 cells analyzed in three independent assays are shown. C, HEK293
cells were cotransfected with various amino-terminal truncations of pEGFP-
DLC-1 and with RhoA(Q63L) or control vector. The overall cell shapes as well
as the localization of DLC-1 were imaged as above.
.
. .
FIGURE 5. Migration of cells transfected with various truncations or
mutations of DLC-1. For migration experiments HEK293 cells transfected
with various truncation constructs or mutants of DLC-1 were plated on
fibronectin-coated (10 g/ml) 35-mm glass-bottomed culture dishes for 30
min to 1 h. Digital images were taken every 5 min for a total of 6 h/experiment.
A, the migration speeds of the cells (15–25 cells/condition) were determined
by dividing the total length of migration path by the total time elapsed.
B, directional persistence (D/T) was determined by dividing the net displace-
ment (D) by total length of the migration path (T). A and B illustrate results for
HEK293 cells transfected with various pEGFP-DLC-1 constructs or treated
with the Rho kinase inhibitor Y27632. In B only the DLC-1 SAM transfected
cells (star) displayed a statistically significant difference from EGFP trans-
fected controls. This observation was repeated in several independent exper-
iments. C, MDA-MB-231 cells were transfected with various DLC-1 truncation
constructs and migration speeds of the cells (15–20 cells/condition) were
determined as described above.
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period, a cell expressing DLC-1 SAM changed direction 10
times in less than 200 min.
The Amino-terminal Domain of DLC-1 Acts as a Dominant
Negative to Block Cell Migration—We had evaluated a GAP-
deficient variant of activatedDLC-1 (DLC-1SAM (R718E)) as
a control to verify that the enhancement in velocity was due to
inactivation of Rho GTPase function. Unexpectedly, we
observed that DLC-1 SAM (R718E), which we anticipated to
be an inactive protein, rendered cells almost completely immo-
bile (Fig. 5A). We then addressed the possibility that DLC-1
SAM (R718E) may function as a dominant inhibitory mutant
by antagonizing endogenous DLC-1 association with focal
adhesions. If so, then the isolated amino-terminal region of
DLC-1, which localizes at focal adhesions, should also inhibit
cell motility. To probe this further, we compared the effects of
expressing the isolated amino-terminal domain (DLC-1 N1
(1–638)) versus the same amino-terminal fragment that con-
tains a missense mutation (Y442F) at the site reported (22, 25)
to be involved in binding to tensins and required for focal adhe-
sion association (Fig. 1). We also examined an amino-terminal
fragment of DLC-1, DLC-1 N2 (1–251), which is truncated
prior to the tensin-binding site. As seen in Fig. 5A, a striking
differencewas observed, with thewild typeDLC-1N1 causing a
marked inhibition of cell motility, whereas the two tensin bind-
ing-deficient amino-terminal fragments were without effect.
These results suggest that the isolated wild type amino-termi-
nal domain of DLC-1 can act as a dominant inhibitor of cell
migration that is dependent on association with tensin and
focal adhesions.
We also performed a similar series of cell migration experi-
ments inMDA-MB-231 cells (Fig. 5C). These results were sim-
ilar to those seen in HEK293 cells, even though the expression
levels of the various DLC-1 constructs were substantially lower
(data not shown). Thus constitutively activated DLC-1 SAM
enhanced cell migration velocity, whereas dominant negative
DLC-1 SAM (R718E) or DLC-1 N1 strongly inhibited cell
movement.
The Amino-terminal Domain Can Displace DLC-1 from
Focal Adhesion Sites—Our observations with HEK293 and
MDA-MB-231 cell lines (Fig. 5) suggested that DLC-1 activity
at focal adhesion sites may be critical for cell motility and that
expression of the native amino-terminal domain constructmay
displace endogenousDLC-1 and thus blockmotility.We exam-
ined this by determining whether amino-terminal fragments of
DLC-1 (N 252–1091 or N 252–508) that strongly associate
with focal adhesions but are not recognized by the monoclonal
antibody that reacts with the region amino acids 47–249 can
disrupt endogenous DLC-1 subcellular localization. As seen in
Fig. 7, expression of these constructs in MDA-MB-231 cells
resulted in reduced levels of endogenous DLC-1 at focal adhe-
sion sites. This suggests that the dominant negative effect of the
amino-terminal domain could be due to displacement of
endogenous DLC-1 from focal adhesions, possibly by blocking
its interaction with tensin.
FIGURE 6. Active DLC-1 reduces persistence of cell movement. The images
were taken at the indicated time (min) and illustrate the rapid changes in
directionality (lack of persistence) in cells transiently transfected with pEGFP-
DLC-1 SAM as compared with control cells transfected with the pEGFP
empty vector. The arrows indicate the direction of cell movement. The images
presented are representative of multiple observations.
FIGURE 7. The amino terminus of DLC-1 displaces endogenous DLC-1
from focal contacts. MDA-MB-231 cells were transiently transfected with
pEGFP, pEGFP-DLC-1 N (252–508), or pEGFP-DLC-1 N (252–1091, R718E).
These proteins retain the tensin-binding sequence that leads to focal adhe-
sion localization but do not have Rho GAP activity, nor are they recognized by
the antibody that binds full-length DLC-1. Transfected cells were then were
replated on fibronectin-coated coverslips (10 g/ml) for 4 –5 h and stained
with anti-DLC-1 monoclonal antibodies (to visualize endogenous DLC-1) fol-
lowed by anti-mouse secondary antibodies conjugated to Alexa Fluor 594
and imaged with a confocal fluorescence microscope. The arrows indicate the
focal adhesions. Scale bar, 10 m. The images presented are representative of
multiple observations.
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DLC-1 Affects Cell Protrusions—Another aspect of DLC-1
function was also revealed from our live cell imaging analyses.
Initially we interpreted the long projections seen in cells
expressing highly active DLC-1 as tail retraction fibers caused
by a reduction in RhoA activity (2). However, it is clear that cells
expressing active DLC-1 also showed a high degree of protru-
sive activity. Thus, as illustrated in Fig. 6, cells that express
activatedDLC-1SAMdisplayed extensive ruffledmembranes
that rapidly switch direction, as well as displaying multiple
branched projections. Some of these projections were due to
defects in tail retraction. However, in addition to retraction
fibers, the cells expressing constitutively activated DLC-1 also
clearly displayed enhanced protrusive activity, with many cells
with rapidly extending long, branched, neurite-like projections
(see supplemental Fig. S4).
DISCUSSION
Restoration ofDLC-1 activity inDLC-1-deficient tumor cells
causes reduced growth rates, restores a more normal pheno-
type (7, 8, 17), and impairs invasion and metastasis (30).
Because a key aspect of DLC-1 involves inhibition of Rho func-
tion and Rho GTPases are implicated in cell motility, in the
present study we focused on the role of DLC-1 function in reg-
ulation of actin organization, focal contact organization, and
cell migration (note: additional images of the subcellular local-
ization of various DLC-1 constructs and their relation to focal
adhesions are presented in supplemental Figs. S5–S10). We
undertook a structure-function analysis to evaluate the contri-
butions of the various domains of DLC-1 to its overall effects on
the RhoGAP activity and its consequences on actin cytoskeletal
organization, cellmorphology, and cellmotility. First, we deter-
mined that the amino-terminal SAM domain is a negative reg-
ulator of the intrinsic RhoGAP activity in vitro and in vivo.
Second, we established that a DLC-1 variant lacking the SAM
domain had strong effects on the velocity and directionality of
cell migration. Further, the isolated amino terminus (positions
1–638) can function as a dominant inhibitory variant of DLC-1
and dramatically reduce migration.
DLC-1 is a multi-functional protein with additional domains
and sequences beyond its RhoGAP catalytic sequences. These
additional sequences may regulate RhoGAP activity as well as
dictate RhoGAP-independent functions of DLC-1. In previous
work we had shown that deletion of both amino- and carboxyl-
terminal domain sequences resulted in a very active core
RhoGAP domain (5). Here we show that deletion of the SAM
domain alone substantially increased DLC-1 RhoGAP activity
both in in vitro assays and within cells. The underlying mecha-
nism is unclear at this point. One possibility is that the amino-
terminal SAM domain regulates the catalytic domain via an
intramolecular interaction. This type of regulation has been
seen commonly in RhoGEFs and to a lesser extent in other
RhoGAPs (1, 3, 4). Alternatively intermolecular interactions or
the recruitment of accessory regulatory proteins may be
involved. In any case, we suggest that the SAM domain may
facilitate stimulus-mediated post-transcriptional mechanisms
for the regulation of the intrinsic RhoGAP activity of DLC-1.
Furthermore, because the signaling mechanisms that activated
DLC-1 function remain to be identified, similar to activated
mutants of Rho GTPases, this constitutively activated DLC-1
variant will be a very useful reagent for further delineation of
DLC-1 activity in normal and neoplastic cell biology.
Expression of the active DLC-1 SAM results in profound
changes in cytoskeletal organizationwith the loss of actin stress
fibers and reduction of focal adhesions. However, by reverting
the effects of DLC-1SAMwith a constitutively active Rho, we
show that DLC-1 SAM retains the ability to localize to focal
contacts and thus can be a properly localized activated GAP.
Expression of DLC-1 SAM also profoundly affects cell migra-
tion, leading to an increase in velocity but a reduction in direc-
tionality. The dual effect of DLC-1 SAM on cell velocity and
directionality may be due to the fact that this protein has GAP
activity for bothRho and forCdc42, a keymediator of cell polar-
ity (2, 5). Interestingly expression of the highly active construct
DLC-1 RhoGAP fails to mimic the effect of DLC-1SAM, sug-
gesting that bothGAP activity and as yet undefined functions of
the amino-terminal domain are essential for DLC-1 effects on
cell motility. By contrast, the change in cell morphology result-
ing from expression of an activated DLC-1 is not dependent on
the presence of amino-terminal sequences.
As expected, expression of the RhoGAP domain containing
the inactivating R718E mutation had little effect on migration,
indicating the critical role of GAP activity in motility. Surpris-
ingly, however, expression of full-length DLC-1 containing the
GAP-inactive R718E mutation caused a profound reduction in
cell movement. Similarly, the isolated amino-terminal frag-
ment had the same inhibitory action. This effect was not seen
with a mutated version (Y442F) of the amino-terminal domain
that fails to bind to the focal adhesion protein tensin, suggesting
that focal contact localization is a key to these effects. The wild
type version, but not the Y442F version, of the amino-terminal
domain was able to displace endogenous DLC-1 from focal
adhesions. Because DLC-2 and DLC-3 share similar tensin-
binding sequences, it seems likely that the isolated DLC-1 ami-
no-terminal can also displace endogenousDLC-2 andDLC-3 as
well. Thus these observations argue that proper placement of
appropriate (endogenous) levels of DLC family members at
focal adhesions is critical for the maintenance of normal cell
motility. Finally, we have found that interfering RNA suppres-
sion of endogenous DLC-1 in lung and breast cancer cells typ-
ically does not result in a robust biological consequences (data
not shown), most likely because of the continued expression of
the functionally relatedDLC-2 andDLC-3 isoforms. Therefore,
this dominant inhibitory mutant of DLC-1, similar to the dom-
inant inhibitory Rho GTPase mutants that block the activity of
multiple Rho activators, will be an important reagent for fur-
ther dissection of role ofDLC loss of function in tumor progres-
sion and growth.
The mechanism(s) underlying the key role of DLC-1 in cell
movement is not clearly understood. One likely possibility is
that it may be critical to facilitate a precise spatial inactivation
of RhoAactivity to supportmigration. Consistentwith this pos-
sibility, we recently found that ectopic expression of wild type
DLC-1 caused inactivation of RhoApreferentially at the leading
edge of migrating cells (5). Our observations on DLC-1 and cell
migration seem consistent with a recently published model of
the mechanisms relating lamellipodial activity and adhesion
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site formation (31). In this model, forward motion of the lead-
ing edge involves localized actin extension, adhesion formation,
contraction, and backward flow of actin, all in balance. When
DLC-1 is active, Arp 2/3 complex-mediated actin protrusion
continues (even if Rac activity is not increased), but contractil-
ity and adhesion site formation will be reduced as Rho/ROCK
activity goes down; this tilts the balance toward rapid leading
edge protrusion and rapidmigration.WhenDLC-1 is displaced
from adhesion sites, for example by the amino-terminal frag-
ment, local Rho is greatly activated, leading to increased con-
tractility, to enhanced strength of focal adhesions, and to
enhanced backward retraction of actin and thus paralysis of
motion.
An interesting observation is that expression of activated
DLC-1 stimulated extensive protrusive activity, but the mech-
anistic basis for these events is unclear. There is a well estab-
lished antagonism between Rho and Rac in regulation of the
cytoskeleton and protrusive activity (32). This antagonismmay
be based in part on FilGAP, a filamin-binding RacGAP that is
negatively regulated by Rho and ROCK and reciprocally on
down-regulation of Rho via Rac-generated reactive oxygen spe-
cies (33, 34). Thus a reduction in Rho activity by DLC-1 could
lead to an increase in Rac activity that would enhance cell pro-
trusions. However, we have not been able to detect an overall
increase in Rac-GTP loading in cells expressing activated
DLC-1 (data not shown); possibly the effects are localized
and difficult to detect at the biochemical level. In neuronal
cells p190RhoGAP has been shown to play a positive role in
axon extension and branching morphogenesis through sup-
pression of an axon retraction pathway mediated by Rho and
ROCK (35, 36). Our observations suggest that RhoGAPs,
particularly DLC-1, may also play a key role in supporting
protrusive activity.
In summary, our structure-function analyses established two
critical roles for two distinct amino-terminal sequence ele-
ments in regulating DLC-1. Whereas the SAM domain func-
tions as an autoinhibitory element of intrinsic RhoGAP cata-
lytic activity, the tensin-binding sequences are critical for
DLC-1 localization to focal adhesions, which is critical for reg-
ulation of cellmigration.Our preliminary analyses of additional
amino-terminal deletion mutants have identified a second
autoinhibitory sequence that coincides with sequences impor-
tant for tensin binding. Hence, our future studies will focus on
determining whether tensin binding may also serve as a mech-
anism to regulate both the spatial and intrinsic activity of
DLC-1. Finally, our studies additionally identified both gain-of-
function and dominant negative variants of DLC-1 that will be
very useful reagents for further delineation of the role of DLC-1
loss in human oncogenesis.
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